Navigation Links
HeartWare to Present at Eighth Annual JMP Securities Research Conference
Date:5/12/2009

FRAMINGHAM, Mass. and SYDNEY, May 12 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN) today announced that it is scheduled to make an investor presentation at the Eighth Annual JMP Securities Research Conference at 12:30 p.m. PT (3:30 p.m. ET) on Tuesday, May 19, 2009. The conference is being held at the Ritz-Carlton, San Francisco May 18-20.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. An archived replay of the presentation will be available shortly after the presentation time for a period of 90 days.

About HeartWare International, Inc.

HeartWare International, Inc. develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs), to treat patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM) pump, the only full-output pump designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has completed an international clinical trial for the device involving five investigational centres in Europe and Australia. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.

    For further information:

    www.heartware.com                               US Investor Relations
    Howard Leibman                                  Matt Clawson
    Director Corporate Development                  Partner
    HeartWare International, Inc.                   Allen & Caron Inc
    Email. howard.leibman@heartware.com.au          Email. matt@allencaron.com
    Tel.  +61 2 9238 2064                           Tel.  +1 949 474 4300


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. HeartWare Selects Allen & Caron for Investor Relations and Corporate Communications
2. HeartWare Announces Move to an Expanded, Upgraded Manufacturing Facility
3. HeartWare Receives Conditional Approval of IDE
4. HeartWare to Present at Seventh Annual JMP Securities Research Conference
5. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
6. Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission
7. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
8. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
9. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
10. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... 2017 , ... Grass pollen is the main cause of hay fever in the United States, ... grass pollen runs from May to July each year; with the worst time for sufferers ... allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs ... store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these ... Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce Arterial ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... -- Wound care devices and products are used to ... industry mainly consists of establishments engaged in manufacturing wound ... caused by mechanical, chemical, thermal, and radiogenic trauma; and ... skin related diseases, immunological diseases, and other chronic diseases. ... largest region in the wound care devices market in ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
Breaking Medicine Technology: